Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
The new tranche of USD 30 million comes in addition to the USD 93 million already committed by BARDA since…
BEAM at work
Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.
